Benzinga

Benzinga

Benzinga

domingo, septiembre 06

Sangamo Therapeutics Inc

SGMOOTC
Trade with Public
Trade with Public
$0.1776
al cierre: May 14, 5:00 PM EST
$0.0777
-0.0999-56.25%
After hour: Jun 23, 9:29 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadComparar

Sangamo Therapeutics Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sangamo Therapeutics Inc (SGMO).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+5961.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Feb 10, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$10
Nov 7, 2025BarclaysGena WangDowngradeOverweight→Equal-Weight$5→$1
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the price target from $5 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $9 to $5.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved